BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...collective valuation of $10.5 billion. The fourth, Caribou Biosciences Inc....
BioCentury | Oct 7, 2020
Tools & Techniques

Doudna and Charpentier, CRISPR pioneers behind a spate of gene editing companies, awarded Nobel Prize

...California Berkeley Intellia Therapeutics Inc. CRISPR Therapeutics AG Editas Medicine Inc. Caribou Biosciences Inc. CRISPR chs2020 doudna charpentier...
BioCentury | Oct 6, 2020
Emerging Company Profile

Scribe: engineering CRISPR’s next generation

...IP from either UC or Broad are CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics Inc. (NASDAQ:NTLA), Caribou Biosciences Inc....
BioCentury | Sep 11, 2020
Politics, Policy & Law

Broad Institute holds its ground in CRISPR IP dispute

...Inc. (NASDAQ:EDIT) has rights to the Broad’s IP for therapeutics, while Intellia Therapeutics Inc. (NASDAQ:NTLA), Caribou Biosciences Inc....
...for therapeutic applications. Lauren Martz Broad Institute of MIT and Harvard University of California Berkeley Editas Medicine Inc. CRISPR Therapeutics AG Caribou Biosciences Inc. Intellia...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

...Co. Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV) and Celgene Corp. (see “Dragonfly’s TriNKETs” ). CRISPR company Caribou Biosciences Inc....
...in the role full-time. Robin Sawka, BioCentury Staff Gossamer Bio Inc. Ascendis Pharma A/S Seer Inc. Jazz Pharmaceuticals plc Dragonfly Therapeutics Inc. Caribou Biosciences Inc. Bolt...
BioCentury | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

...CRISPR-HIV Therapy to Clinic" ). Caribou’s Type I CRISPR gene editing tool Gene editing company Caribou Biosciences Inc....
...Microtubule-associated protein τ; TNFRS11B (OPG) - Tumor necrosis factor receptor superfamily member 11b BioCentury Staff Excision BioTherapeutics Inc. Caribou Biosciences Inc. Kymab...
BioCentury | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

...Task Force: Audentes Therapeutics Inc. (NASDAQ:BOLD); bluebird bio Inc. (NASDAQ:BLUE); BlueRock Therapeutics L.P. (Cambridge, Mass.), Caribou Biosciences Inc....
...Pharmacopeia and the International Organization for Standardization. Steve Usdin, Washington Editor Audentes Therapeutics Inc. bluebird bio Inc. BlueRock Therapeutics L.P. Caribou Biosciences Inc. Casebia...
BioCentury | Mar 12, 2019
Company News

UC strengthens CRISPR IP position with new patent

...and Patent No.10,113,167 covers protein/RNA compositions that can be used to deliver CRISPR-Cas9 into cells. Caribou Biosciences Inc....
BioCentury | Feb 8, 2019
Company News

USPTO to grant UC foundational CRISPR patent

...the allowance. Instead, those patents described a two-part system containing Cas9 and the mature crRNA. Caribou Biosciences Inc....
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

...BioCentury Online Intelligence; NIST website Name Location Biopharma companies bluebird bio Inc. (NASDAQ:BLUE) Cambridge, Mass. Caribou Biosciences Inc....
...company is not doing work on the germline, and has no plans to do so. Caribou Biosciences Inc....
...off-target indels and on-target changes,” he said. Companies and Institutions Mentioned Beam Therapeutics, Cambridge, Mass. Caribou Biosciences Inc....
Items per page:
1 - 10 of 74
BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...collective valuation of $10.5 billion. The fourth, Caribou Biosciences Inc....
BioCentury | Oct 7, 2020
Tools & Techniques

Doudna and Charpentier, CRISPR pioneers behind a spate of gene editing companies, awarded Nobel Prize

...California Berkeley Intellia Therapeutics Inc. CRISPR Therapeutics AG Editas Medicine Inc. Caribou Biosciences Inc. CRISPR chs2020 doudna charpentier...
BioCentury | Oct 6, 2020
Emerging Company Profile

Scribe: engineering CRISPR’s next generation

...IP from either UC or Broad are CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics Inc. (NASDAQ:NTLA), Caribou Biosciences Inc....
BioCentury | Sep 11, 2020
Politics, Policy & Law

Broad Institute holds its ground in CRISPR IP dispute

...Inc. (NASDAQ:EDIT) has rights to the Broad’s IP for therapeutics, while Intellia Therapeutics Inc. (NASDAQ:NTLA), Caribou Biosciences Inc....
...for therapeutic applications. Lauren Martz Broad Institute of MIT and Harvard University of California Berkeley Editas Medicine Inc. CRISPR Therapeutics AG Caribou Biosciences Inc. Intellia...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

...Co. Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV) and Celgene Corp. (see “Dragonfly’s TriNKETs” ). CRISPR company Caribou Biosciences Inc....
...in the role full-time. Robin Sawka, BioCentury Staff Gossamer Bio Inc. Ascendis Pharma A/S Seer Inc. Jazz Pharmaceuticals plc Dragonfly Therapeutics Inc. Caribou Biosciences Inc. Bolt...
BioCentury | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

...CRISPR-HIV Therapy to Clinic" ). Caribou’s Type I CRISPR gene editing tool Gene editing company Caribou Biosciences Inc....
...Microtubule-associated protein τ; TNFRS11B (OPG) - Tumor necrosis factor receptor superfamily member 11b BioCentury Staff Excision BioTherapeutics Inc. Caribou Biosciences Inc. Kymab...
BioCentury | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

...Task Force: Audentes Therapeutics Inc. (NASDAQ:BOLD); bluebird bio Inc. (NASDAQ:BLUE); BlueRock Therapeutics L.P. (Cambridge, Mass.), Caribou Biosciences Inc....
...Pharmacopeia and the International Organization for Standardization. Steve Usdin, Washington Editor Audentes Therapeutics Inc. bluebird bio Inc. BlueRock Therapeutics L.P. Caribou Biosciences Inc. Casebia...
BioCentury | Mar 12, 2019
Company News

UC strengthens CRISPR IP position with new patent

...and Patent No.10,113,167 covers protein/RNA compositions that can be used to deliver CRISPR-Cas9 into cells. Caribou Biosciences Inc....
BioCentury | Feb 8, 2019
Company News

USPTO to grant UC foundational CRISPR patent

...the allowance. Instead, those patents described a two-part system containing Cas9 and the mature crRNA. Caribou Biosciences Inc....
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

...BioCentury Online Intelligence; NIST website Name Location Biopharma companies bluebird bio Inc. (NASDAQ:BLUE) Cambridge, Mass. Caribou Biosciences Inc....
...company is not doing work on the germline, and has no plans to do so. Caribou Biosciences Inc....
...off-target indels and on-target changes,” he said. Companies and Institutions Mentioned Beam Therapeutics, Cambridge, Mass. Caribou Biosciences Inc....
Items per page:
1 - 10 of 74